Cargando…
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
In the era of highly promising novel targeted-immunotherapy strategies for multiple myeloma (MM), the first series of clinical trials with CAR T-cells targeting the plasma cell-specific B-cell maturation antigen (BCMA) have shown excellent response rates. In the long-term, however, MM appears to esc...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419675/ https://www.ncbi.nlm.nih.gov/pubmed/32850436 http://dx.doi.org/10.3389/fonc.2020.01362 |